DATROWAY
DATROWAY is a Trop-2-directed antibody-drug conjugate indicated for the treatment of specific advanced lung and breast cancers. It is used in adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have previously undergone EGFR-directed therapy and platinum-based chemotherapy. Additionally, it is approved for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer following prior endocrine-based therapy and chemotherapy. The lung cancer indication is granted under accelerated approval, with continued approval dependent on the verification of clinical benefit in confirmatory trials.
How DATROWAY Works
Datopotamab deruxtecan-dlnk consists of a humanized anti-Trop2 antibody linked to a topoisomerase I inhibitor payload called DXd. The drug binds to Trop-2 receptors on the surface of tumor cells and is internalized into the cell, where lysosomal enzymes cleave the linker to release the payload. Once released, the membrane-permeable DXd causes DNA damage and triggers apoptotic cell death. This targeted delivery system allows for anti-tumor activity specifically in cells expressing Trop-2.
Details
- Status
- Prescription
- First Approved
- 2025-01-17
- Routes
- IV (INFUSION), INJECTION
- Dosage Forms
- INJECTABLE
DATROWAY Approval History
What DATROWAY Treats
2 indicationsDATROWAY is approved for 2 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Non-Small Cell Lung Cancer
- Breast Cancer
DATROWAY Target & Pathway
ProTarget
A receptor that triggers cell growth, proliferation, and survival when activated. Mutations or overexpression of EGFR drive many cancers, particularly lung cancer. Blocking EGFR stops the growth signals that fuel tumor progression.
DATROWAY Competitors
Pro10 other drugs also target EGFR. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (EGFR). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to DATROWAY
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DATROWAY FDA Label Details
ProIndications & Usage
FDA Label (PDF)DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. a...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.